Last reviewed 2006-07-18 · How we verify
Home › Trials › NCT00035971 EVA: Evista Alendronate Comparison
NCT00035971
Phase 4
COMPLETED
The purpose of this study is to determine how treatment with raloxifene compares to treatment with alendronate in postmenopausal women with osteoporosis on the chance of experiencing fractures
Details
Lead sponsor Eli Lilly and Company Phase Phase 4 Status COMPLETED
Conditions
Interventions raloxifene HCI and alendronate Na Countries United States, Canada
Source: ClinicalTrials.gov. Drug Landscape entry: https://druglandscape.com/trial/NCT00035971.
See also: ClinicalTrials.gov record .
Not medical advice. Information on this page is collated from primary regulatory and clinical-trial sources for research purposes. It is not a substitute for consultation with a licensed healthcare professional. See our editorial policy for sourcing and methodology.